Nirmatrelvir/ritonavir: real world drug-drug interaction management experience

被引：0
|
作者：
Bukhari, Shahid [1 ]
Hughes, Stephen [1 ]
Mughal, Nabeela [1 ]
Moore, Luke S. P. [1 ,2 ,3 ]
Davies, Gary [1 ]
Zhang, Adrian Varghas [2 ]
Ng, Megan [2 ]
Karagozlu, Zekiye [2 ]
Boffito, Marta [1 ,2 ]
机构：
[1] Chelsea & Westminster Hosp Fdn Trust, London, England
[2] Imperial Coll London, London, England
[3] Imperial Coll Healthcare NHS Trust, North West London Pathol, London, England
来源：
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2024年 / 22卷 / 09期
关键词：
Nirmatrelvir/ritonavir; drug-drug interactions; COVID-19; Paxlovid; real world;
D O I：
10.1080/14787210.2024.2389884
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
BackgroundIn the UK, a regional vertical system for the delivery of COVID-19 medicines has been in place. This enabled centralization of expertise in risk stratification of patients, and in understanding and mitigating drug-drug interactions.Research design and methodsWe analyzed real-world drug-drug interactions in adult patients referred for nirmatrelvir/ritonavir therapy across one such geographic area covering 2.2 million London citizens.ResultsAmong 208 who received NMV/r therapy, we identified 184 potential DDIs, 8% precluded nirmatrelvir/ritonavir use, 53% required management, but 56% of these did not have documented advice to hold therapy.ConclusionsThis highlights the need to maintain and develop pathways for clinical pharmacology expertise in COVID-19 management.
引用
收藏
页码：781 / 783
页数：3
相关论文
共 50 条
  • [31] AB-ITALY: The impact of drug-drug interaction on abemaciclib treatment in Italian real world experience
    Botticelli, A.
    Scagnoli, S.
    Pisegna, S.
    Toss, A.
    Fabi, A.
    Criscitiello, C.
    D'Auria, G.
    Fabbri, M. A.
    Orlandi, A.
    Barberi, V.
    Caputo, R.
    Vici, P.
    Palleschi, M.
    Santini, D.
    Tomasello, G.
    Ricevuto, E.
    Simmaco, M.
    Preissner, R.
    Cortesi, E.
    Marchetti, P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S659 - S660
  • [32] Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide
    de Requena, Daniel Gonzalez
    Calcagno, Andrea
    Bonora, Stefano
    Ladetto, Laura
    D'Avolio, Antonio
    Sciandra, Mauro
    Siccardi, Marco
    Bargiacchi, Olivia
    Sinicco, Alessandro
    Di Perri, Giovanni
    AIDS, 2006, 20 (15) : 1977 - 1979
  • [33] Management of drug-related problems including drug-drug interactions caused by nirmatrelvir/ritonavir in paediatric patients with SARS-CoV-2
    Yalcin, Nadir
    Demirkan, Kutay
    ARCHIVES OF DISEASE IN CHILDHOOD, 2023, 108 (10)
  • [34] Safety pro file of nirmatrelvir-ritonavir: Evidence of adverse events due to drug-drug interactions
    Gonzalez-Gomez, Alvaro
    Caro-Teller, Jose Manuel
    Gonzalez-Barrios, Ivan
    Castro-Frontinan, Almudena
    Rodriguez-Quesada, Pedro Pablo
    Ferrari-Piquero, Jose Miguel
    FARMACIA HOSPITALARIA, 2024, 48 (02) : 70 - 74
  • [35] Drug-drug interaction of Nirmatrelvir/ritonavir and tacrolimus: A potential risk disproportionality analysis of nephrotoxicity from COVID-19 reports in FAERS
    Qin, Fuhong
    Wang, Huiling
    Li, Meng
    Zhuo, Shengnan
    Liu, Wei
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (12) : 1321 - 1327
  • [36] Nirmatrelvir+ritonavir/tacrolimusDrug toxicity following drug-drug pharmacokinetic interaction leading to anuric acute kidney injury : case report
    Reactions Weekly, 2023, 1983 (1) : 364 - 364
  • [37] Drug-Drug Interaction Analysis of Pyronaridine/Artesunate and Ritonavir in Healthy Volunteers
    Morris, Carrie A.
    Lopez-Lazaro, Luis
    Jung, Donald
    Methaneethorn, Janthima
    Duparc, Stephan
    Borghini-Fuhrer, Isabelle
    Pokorny, Rolf
    Shin, Chang-Sik
    Fleckenstein, Lawrence
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2012, 86 (03): : 489 - 495
  • [38] Unexpected drug-drug interaction between amprenavir (APV) and ritonavir (RTV)
    Poirier, J. M.
    Meynard, J. L.
    Guiard-Schmid, J. B.
    Morand-Joubert, L.
    Schneider, V.
    Jacquemet, N.
    Girard, P. M.
    Rozenbaum, W.
    Jaillon, P.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2001, 15 : 65 - 65
  • [39] Drug-Drug Interaction Between Itraconazole and the Protease Inhibitor Lopinavir/Ritonavir
    Hills-Nieminen, Cara
    Hughes, Christine A.
    Houston, Stan
    Shafran, Stephen D.
    ANNALS OF PHARMACOTHERAPY, 2009, 43 (12) : 2117 - 2120
  • [40] Drug-Drug Interaction Study of Ketoconazole and Ritonavir-Boosted Saquinavir
    Kaeser, Benoite
    Zandt, Hagen
    Bour, Fabrice
    Zwanziger, Elke
    Schmitt, Christophe
    Zhang, Xiaoping
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (02) : 609 - 614
12345